Milton H. Werner - 21 Jan 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
President and CEO, Director
Signature
/s/ Milton H. Werner
Issuer symbol
IKT
Transactions as of
21 Jan 2025
Net transactions value
$0
Form type
4
Filing time
22 Jan 2025, 16:05:06 UTC
Previous filing
07 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -3,643 -100% $0.000000 0 21 Jan 2025 Common Stock 3,643 $13.86 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +3,643 $0.000000 3,643 21 Jan 2025 Common Stock 3,643 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -3,643 -100% $0.000000 0 21 Jan 2025 Common Stock 3,643 $13.86 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +3,643 $0.000000 3,643 21 Jan 2025 Common Stock 3,643 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -3,643 -100% $0.000000 0 21 Jan 2025 Common Stock 3,643 $13.86 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +3,643 $0.000000 3,643 21 Jan 2025 Common Stock 3,643 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -3,643 -100% $0.000000 0 21 Jan 2025 Common Stock 3,643 $28.76 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +3,643 $0.000000 3,643 21 Jan 2025 Common Stock 3,643 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -3,643 -100% $0.000000 0 21 Jan 2025 Common Stock 3,643 $33.43 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +3,643 $0.000000 3,643 21 Jan 2025 Common Stock 3,643 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -16,667 -100% $0.000000 0 21 Jan 2025 Common Stock 16,667 $60.00 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +16,667 $0.000000 16,667 21 Jan 2025 Common Stock 16,667 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -20,834 -100% $0.000000 0 21 Jan 2025 Common Stock 20,834 $6.42 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +20,834 $0.000000 20,834 21 Jan 2025 Common Stock 20,834 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -35,000 -100% $0.000000 0 21 Jan 2025 Common Stock 35,000 $4.44 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +35,000 $0.000000 35,000 21 Jan 2025 Common Stock 35,000 $1.26 Direct F1, F2, F3
transaction IKT Stock Option (Right to Buy) Disposed to Issuer $0 -45,000 -100% $0.000000 0 21 Jan 2025 Common Stock 45,000 $2.16 Direct F2, F3
transaction IKT Stock Option (Right to Buy) Award $0 +45,000 $0.000000 45,000 21 Jan 2025 Common Stock 45,000 $1.26 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
F2 The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F3 This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.